The efficacy and role ofanti-lipid mediators on pulmonary fibrosis
Project/Area Number |
22590871
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Respiratory organ internal medicine
|
Research Institution | Keio University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
ASANO Koichiro 慶應義塾大学, 医学部, 准教授 (60192944)
|
Co-Investigator(Renkei-kenkyūsha) |
ARITA Makoto 東京大学, 大学院・薬学系研究科, 准教授 (80292952)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 肺線維症 / 抗炎症性脂質メディエーター / 不飽和脂肪酸 |
Research Abstract |
Pulmonary fibrosis is a progressive disease of unknown etiology and poor prognosis because there is no effective therapy. In the current study, using an experimental murine model of pulmonary fibrosis, EPA derived resolving E1 (RvE1) and high dose of EPA
|
Report
(4 results)
Research Products
(5 results)